title: Agomelatine as a novel treatment option in panic disorder, results from an 8-week open-label trial.
authors: Department of Psychiatry VU University Medical Centre and Department of Anxiety and Depression GGZ inGeest Amsterdam, The Netherlands khuijbregts@gmail.com Department of Psychiatry VU University Medical Centre Department of Anxiety and Depression GGZ inGeest and EMGO Institute for Health and Care Research (EMGO+) Amsterdam, The Netherlands Department of Psychiatry VU University Medical Centre, and GGZ inGeest Amsterdam, The Netherlands Department of Psychiatry VU University Medical Centre and Department of Anxiety and Depression GGZ inGeest Amsterdam, The Netherlands Department of Psychiatry VU University Medical Centre Department of Anxiety and Depression GGZ inGeest and EMGO Institute for Health and Care Research (EMGO+) Amsterdam, The Netherlands.
authors: Klaas M
authors: KM
authors: Huijbregts
authors: Neeltje M
authors: NM
authors: Batelaan
authors: Judy
authors: J
authors: Schonenberg
authors: Gerthe
authors: G
authors: Veen
authors: Anton J
authors: AJ
authors: van Balkom
mesh_terms: D000081:Acetamides / Q000627:therapeutic use*; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016584:Panic Disorder / Q000188:drug therapy*; D009281:Naphthalenes
chemical_list: D000081:Acetamides; D014151:Anti-Anxiety Agents; C084711:agomelatine; D009281:Naphthalenes